John E Langenfeld

US Patent:

20020159986, Oct 31, 2002

Filed:

Jan 11, 2002

Appl. No.:

10/044716

Inventors:

John Langenfeld - Flemington NJ, US

International Classification:

A61K038/43
A61K038/17

US Classification:

424/094100, 514/012000

Abstract:

The present invention pertains to the use of BMP-2, which is overexpressed in most common cancers, as 1) a target for cancer treatment therapies and 2) a means to diagnose cancer. The therapeutic component of this invention involves administering to a patient a composition that inhibits bone morphogenetic-2 activity. Such inhibition may be accomplished by ligands or antibodies that bind to BMP-2 or BMP-2 receptors. It may also be achieved by preventing the processing of pro-BMP-2, or blocking transcription or replication of BMP-2 DNA or translation of BMP-2 mRNA. The diagnostic component of the invention involves measuring the BMP-2 level in biological samples from both a patient and a non-cancerous subject and comparing those levels. Elevated levels of BMP-2 in the patient compared to the subject indicate cancer.

US Patent:

20030134790, Jul 17, 2003

Filed:

May 2, 2002

Appl. No.:

10/139814

Inventors:

John Langenfeld - Flemington NJ, US

Assignee:

University of Medicine and Dentistry of New Jersey

International Classification:

A61K038/17
A61K038/43

US Classification:

514/012000

Abstract:

The present invention pertains to the use of BMP-2 and/or BMP-4 as 1) targets for cancer treatment therapies and 2) means to diagnose cancer. The therapeutic component of this invention involves administering to a patient a composition that inhibits bone morphogenetic protein-2 activity and/or bone morphogenetic protein-4 activity. Such inhibition may be accomplished by ligands or antibodies that bind to BMP-2 and/or BMP-4 or receptors for BMP-2 and BMP-4. It may also be achieved by preventing the processing of pro-BMP-2 and/or pro-BMP-4, or blocking transcription or replication of BMP-2 DNA and/or BMP-4 DNA or translation of BMP-2 mRNA and/or BMP-4 mRNA. The diagnostic component of the invention involves measuring the BMP-2 and/or BMP-4 level(s) in biological samples from both a patient and a non-cancerous subject and comparing those levels. Elevated levels of BMP-2 and/or BMP-4 in the patient compared to the subject indicate cancer.

US Patent:

20040126375, Jul 1, 2004

Filed:

Oct 23, 2003

Appl. No.:

10/692824

Inventors:

John Langenfeld - Flemington NJ, US

International Classification:

A61K038/17
A61K039/395

US Classification:

424/145100, 514/012000

Abstract:

The present invention pertains to the use of BMP-2, which is overexpressed in most common cancers, as 1) a target for cancer treatment therapies and 2) a means to diagnose cancer. The therapeutic component of this invention involves administering to a patient a composition that inhibits bone morphogenetic-2 activity. Such inhibition may be accomplished by ligands or antibodies that bind to BMP-2 or BMP-2 receptors. It may also be achieved by preventing the processing of pro-BMP-2, or blocking transcription or replication of BMP-2 DNA or translation of BMP-2 mRNA. The diagnostic component of the invention involves measuring the BMP-2 level in biological samples from both a patient and a subject and comparing those levels. Elevated levels of BMP-2 in the patient compared to the non-cancerous subject indicate cancer.

US Patent:

20060198844, Sep 7, 2006

Filed:

May 17, 2006

Appl. No.:

11/435852

Inventors:

John Langenfeld - Flemington NJ, US

International Classification:

A61K 39/395
A61K 38/17

US Classification:

424145100, 514012000

Abstract:

The present invention pertains to the use of BMP-2, which is overexpressed in most common cancers, as 1) a target for cancer treatment therapies and 2) a means to diagnose cancer. The therapeutic component of this invention involves administering to a patient a composition that inhibits bone morphogenetic-2 activity. Such inhibition may be accomplished by ligands or antibodies that bind to BMP-2 or BMP-2 receptors. It may also be achieved by preventing the processing of pro-BMP-2, or blocking transcription or replication of BMP-2 DNA or translation of BMP-2 mRNA. The diagnostic component of the invention involves measuring the BMP-2 level in biological samples from both a patient and a subject and comparing those levels. Elevated levels of BMP-2 in the patient compared to the non-cancerous subject indicate cancer.

US Patent:

20090214521, Aug 27, 2009

Filed:

Dec 30, 2008

Appl. No.:

12/346266

Inventors:

John Langenfeld - Flemington NJ, US

International Classification:

A61K 39/395

US Classification:

4241301

Abstract:

The present invention pertains to the use of BMP-2, which is overexpressed in most common cancers, as 1) a target for cancer treatment therapies and 2) a means to diagnose cancer. The therapeutic component of this invention involves administering to a patient a composition that inhibits bone morphogenetic-2 activity. Such inhibition may be accomplished by ligands or antibodies that bind to BMP-2 or BMP-2 receptors. It may also be achieved by preventing the processing of pro-BMP-2, or blocking transcription or replication of BMP-2 DNA or translation of BMP-2 mRNA. The diagnostic component of the invention involves measuring the BMP-2 level in biological samples from both a patient and a subject and comparing those levels. Elevated levels of BMP-2 in the patient compared to the non-cancerous subject indicate cancer.

US Patent:

20140256720, Sep 11, 2014

Filed:

Jul 25, 2012

Appl. No.:

14/234616

Inventors:

Charles C. Hong - Nolensville TN, US
John Langenfeld - Flemington NJ, US

Assignee:

UNIVERSITY OF MEDICINE & DENTISTRY OF NEW JERSEY - Somerset NJ
VANDERBILT UNIVERSITY - Nashville TN

International Classification:

C07D 487/04
A61K 31/5377
A61N 5/10
A61K 31/519

US Classification:

5142332, 5142593, 435375, 600 1

Abstract:

Methods for regulating cancer cell growth and survival, inhibiting cancer cell growth, promoting cancer cell death, and/or treating a cancer make use of antagonists of a type I BMP receptor. In some embodiments the cancer is a lung cancer and the cancer cell is a lung cancer cell.